Darvias (darinaparsin) () vs Epkinly (epcoritamab-bysp)
Darvias (darinaparsin) () vs Epkinly (epcoritamab-bysp)
When comparing Darvias (darinaparsin), an organic arsenic derivative with anti-tumor activity, to Epkinly (epcoritamab-bysp), a bispecific antibody targeting CD3 on T cells and CD20 on B cells, it is important to consider their distinct mechanisms of action and indications. Darvias is primarily used for the treatment of peripheral T-cell lymphoma and has shown efficacy in targeting malignant cells through mitochondrial dysfunction and apoptosis. In contrast, Epkinly is designed for the treatment of B-cell non-Hodgkin lymphoma, leveraging the body's immune system to recognize and destroy cancer cells. The choice between the two medications would largely depend on the specific type of lymphoma a patient has and the treatment goals established by the healthcare provider.
Difference between Darvias (darinaparsin) and Epkinly
| Metric | Darvias (darinaparsin) | Epkinly (epcoritamab-bysp) |
|---|---|---|
| Generic name | darinaparsin | epcoritamab-bysp |
| Indications | Currently being investigated for the treatment of various types of cancer, including lymphoma and solid tumors. | Used for the treatment of B-cell non-Hodgkin lymphoma. |
| Mechanism of action | Organic arsenic compound that induces apoptosis and disrupts mitochondrial bioenergetics in cancer cells. | Bispecific antibody targeting CD20 on B-cells and CD3 on T-cells to recruit T-cells to kill B-cell lymphoma. |
| Brand names | Darvias | Epkinly |
| Administrative route | Intravenous | Intravenous |
| Side effects | Fatigue, nausea, vomiting, diarrhea, and abdominal pain. | Infusion-related reactions, cytopenias, infections, fatigue, and fever. |
| Contraindications | Not yet fully established due to ongoing clinical trials. | Hypersensitivity to epcoritamab-bysp or any of its excipients. |
| Drug class | Organic arsenical | Bispecific monoclonal antibody |
| Manufacturer | ZIOPHARM Oncology | Genmab and AbbVie |
Efficacy
Darvias (darinaparsin)
Darvias, with the active ingredient darinaparsin, is a novel organic arsenic compound that has been investigated for its potential efficacy in the treatment of various types of cancer, including lymphoma. Darinaparsin has been shown to induce apoptosis in malignant cells and has demonstrated activity in preclinical models of lymphoma. While the exact mechanism of action is not fully understood, darinaparsin appears to exert its effects through multiple pathways, including the induction of oxidative stress and the inhibition of mitochondrial function in cancer cells.
In clinical trials, darinaparsin has been evaluated for its efficacy in patients with different subtypes of lymphoma, including Hodgkin's lymphoma and certain non-Hodgkin's lymphomas. The results have shown some promise, with a subset of patients experiencing partial or complete responses to the treatment. However, the efficacy of Darvias can vary depending on the type and stage of lymphoma, and further studies are needed to fully establish its role in the treatment of this disease.
Epkinly (epcoritamab-bysp)
Epkinly, known by its generic name epcoritamab-bysp, is a bispecific antibody designed to target both CD3 on T-cells and CD20 on B-cells. This dual targeting mechanism is intended to redirect T-cells to engage and eliminate B-cell lymphomas. Epcoritamab has been studied in clinical trials for its efficacy in treating various B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, among others.
The clinical trials have shown encouraging results, with Epkinly demonstrating the ability to induce responses in a significant proportion of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The observed responses include complete remissions in some patients, suggesting that Epkinly could represent a valuable treatment option for individuals with lymphoma who have exhausted other therapies. As with any investigational treatment, the efficacy of Epkinly will continue to be evaluated in ongoing and future clinical trials to better understand its potential benefits and limitations in the management of lymphoma.
Regulatory Agency Approvals
Darvias (darinaparsin)
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Epkinly
-
Food and Drug Administration (FDA), USA
Access Darvias (darinaparsin) or Epkinly today
If Darvias (darinaparsin) or Epkinly are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us